This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Liver cancer

Glypican 3 (GPC3)

In vitro and mouse studies identified an anti-GPC3 antibody that could help treat hepatocellular carcinoma (HCC). In human HCC cell lines, an antibody against a core functional portion of GPC3 inhibited growth of GPC3+ HCC cells but not GPC3- or GPC3 knockout cells. In a mouse xenograft model for HCC, the antibody decreased tumor growth compared with control antibodies. Next steps include completing preclinical testing.
Chugai Pharmaceutical Co. Ltd. and Roche have the
anti-GPC3 antibody GC33 in Phase II testing to treat liver cancer.
Bristol-Myers Squibb Co. has the anti-GPC3 antibody MDX-1414 in preclinical development for the same indication.

SciBX 6(11); doi:10.1038/scibx.2013.262
Published online March 21, 2013

Patent application filed; available for licensing

Feng, M. et al. Proc. Natl. Acad. Sci. USA; published online March 5, 2013;
doi:10.1073/pnas.1217868110
Contact: Mitchell Ho, National Cancer Institute, Bethesda, Md.
e-mail:
homi@mail.nih.gov